RYAM (RYAM) Q3 2025: $48M Revenue Drop Sharpens Focus on Specialty Pricing Reset
RYAM’s Q3 results marked a pivotal shift as management doubled down on recapturing lost value in cellulose specialties through aggressive pricing resets and structural cost cuts. With non-core paperboard and high-yield pulp segments dragging on results, the company is repositioning its portfolio and capital allocation toward higher-return biomaterials projects and core specialty cellulose. Investors should watch for 2026 pricing negotiations and the ramp of new biomaterial initiatives as the key catalysts for margin expansion and balance sheet flexibility.
Summary
- Specialty Cellulose Pricing Reset: Management targets multi-year price increases to recapture $300 million in lost value from inflation since 2014.
- Portfolio Realignment Accelerates: Non-core assets face further downtime and potential divestiture, as focus shifts to high-margin, specialty-led growth.
- Biomaterials Pipeline Advances: High-return projects like AGE and Bionova are poised to drive outsized EBITDA growth and capital efficiency.
Performance Analysis
RYAM’s third quarter saw revenue slide to $353 million, down $48 million year over year, as non-core paperboard and high-yield pulp segments continued to underperform. Paperboard sales fell 29 percent with margins collapsing to 3 percent, while high-yield pulp EBITDA swung negative on persistent oversupply and shipment delays. Cellulose specialties, the company’s core business, delivered $204 million in sales with margin expansion to 32 percent, reflecting pricing actions and mix improvement despite lower volumes and strike-related disruption in France.
Adjusted EBITDA landed at $42 million, down $9 million versus the prior year, as cost headwinds and strategic downtime offset gains in specialty pricing. Working capital outflows pressured free cash flow, but management expects a $30 million release in Q4 as inventory normalizes. Liquidity remains at $140 million, with a net secured leverage ratio of 4.1 times—well within covenant limits but leaving little room for error.
- Paperboard Drag Intensifies: Lower volumes and pricing, combined with downtime, drove a $10 million EBITDA decline year over year.
- Specialty Margin Expansion: Pricing actions and mix shift lifted cellulose specialties EBITDA margins to 32 percent, up from 28 percent last year.
- Biomaterials Flat but Strategic: Segment sales were steady, but margins compressed as project ramp costs and feedstock constraints weighed on near-term profitability.
Management’s decision to proactively idle non-core lines and monetize inventory traded short-term EBITDA for cash preservation, underscoring a disciplined capital allocation stance in a volatile market.
Executive Commentary
"We are targeting a significant price reset to reflect the inherent value of our cellular specialty products, which we believe requires recapturing lost value from prior years' inflation. Our cost, the $30 million reduction program for 2026, is almost fully implemented."
Delisle Blomquist, President and CEO
"Adjusted free cash flow year-to-date was negative $83 million, driven by working capital timing that is expected to improve in the fourth quarter. We remain focused on driving working capital efficiency and improving cash flow generation."
Marcus Maltner, CFO and Senior Vice President of Finance
Strategic Positioning
1. Specialty Cellulose Pricing Power
RYAM is leveraging its outsized market share and concentrated industry structure—with three players controlling roughly 80 percent of global capacity—to pursue a “significant reset” in specialty cellulose pricing for 2026. Management highlighted that industry inflation has outpaced pricing by 35 percent since 2014, representing an estimated $300 million in lost value to recapture. With capacity utilization above 90 percent and no major additions expected before 2029, the company is positioned to drive multi-year pricing gains well above cost inflation, which is critical for reinvestment and long-term viability.
2. Non-Core Asset Rationalization
Paperboard and high-yield pulp remain under strategic review, with management planning further downtime, cost cuts, and new product launches to restore profitability ahead of a potential divestiture post-2026 USMCA review. Operational milestones for sale include returning to positive EBITDA and cash flow, completing new product commercialization, and resolving trade uncertainties. The Temiscaming site, once profitable, is now expected to lose $14 million EBITDA in 2025, but targeted initiatives are underway to reverse this trend.
3. Biomaterials Growth Engine
RYAM’s biomaterials portfolio is advancing rapidly, with flagship projects like Altamaha Green Energy (AGE) and Bionova bioethanol set to deliver high returns on modest equity investments. The AGE project, for example, is expected to yield $50 million in proportional EBITDA on $46 million of equity, targeting a utility-like 12x ROI. Additional projects in CTO (crude tall oil) and prebiotics feed additives are progressing, leveraging existing infrastructure for capital efficiency and scalability. These initiatives are designed to drive incremental EBITDA of $70 million-plus over the next three years, supporting the company’s ambition to double EBITDA by 2027.
4. Cost Discipline and Automation
Cost reduction remains a cornerstone, with $30 million in structural savings for 2026 nearly fully implemented and a further $20 million in plant and corporate cuts targeted for 2027. Initiatives span utility contract renegotiation, automation, AI-driven clerical reductions, and enhanced maintenance practices. Management also sees upside from ongoing automation and AI, with an additional $4–$6 million in potential savings over the next two to three years.
5. Capital Allocation and Balance Sheet Flexibility
With net secured leverage at 4.1 times, management is prioritizing cash flow generation, working capital release, and selective investment in high-return projects. The company plans to refinance callable debt in 2026, targeting improved terms as EBITDA recovers and the portfolio mix shifts toward higher-margin, lower-volatility businesses. Divestiture of non-core assets is expected to further deleverage the balance sheet, enabling greater flexibility for growth investment and shareholder returns.
Key Considerations
RYAM’s quarter underscores a decisive pivot from legacy commodity exposure toward specialty-led growth and capital-light innovation. Strategic execution in the next 12 months will determine whether the company can unlock the embedded operating leverage in its asset base and deliver on its ambitious EBITDA targets.
Key Considerations:
- Pricing Leverage in a Tight Market: Industry consolidation and high utilization provide a rare window for outsized price resets in specialty cellulose.
- Non-Core Asset Overhang: Paperboard and high-yield pulp remain a drag until operational and trade milestones are met for divestiture.
- Biomaterials Execution Risk: Success of AGE and Bionova projects hinges on securing project financing and timely commercialization.
- Working Capital and Cash Flow Volatility: Timing of inventory releases and customer order patterns may drive quarter-to-quarter swings in free cash flow.
- Balance Sheet Tension: Elevated leverage constrains optionality until EBITDA recovery and asset sales materialize.
Risks
RYAM faces execution risk in delivering specialty pricing gains and commercializing new biomaterials projects, as well as ongoing exposure to trade policy shifts, labor disruptions, and commodity market volatility. Balance sheet leverage remains elevated, and failure to divest non-core assets or achieve working capital targets could limit flexibility and increase refinancing risk in 2026.
Forward Outlook
For Q4 2025, RYAM guided to:
- Adjusted free cash flow turning positive as $30 million in working capital is released
- Continued normalization of core specialty and biomaterials operations
For full-year 2025, management refined guidance to:
- Adjusted EBITDA of $135–$140 million
Management highlighted several factors that will shape 2026 and beyond:
- Specialty cellulose pricing negotiations in late 2025/early 2026 as the key EBITDA lever
- Completion of cost reduction programs and ramp of biomaterials projects as margin catalysts
Takeaways
RYAM’s Q3 signals a strategic inflection, with the company leaning into specialty pricing power and biomaterials innovation to offset legacy headwinds and restore margin expansion.
- Specialty Reset Is the Core Narrative: Multi-year price increases in cellulose specialties are now management’s top priority and the main lever for EBITDA growth.
- Non-Core Drag and Asset Sale Path: Paperboard and high-yield pulp will remain a drag until operational, market, and trade milestones unlock divestiture value.
- Biomaterials Projects Offer High Upside: Early-stage but advancing, these initiatives provide a path to outsized returns and a more durable, capital-light growth profile.
Conclusion
RYAM’s quarter was defined by decisive action on pricing, cost, and portfolio focus, with management demonstrating a clear path to margin expansion and capital efficiency. The next 12 months will test execution on specialty pricing resets and biomaterials ramp, which are critical to realizing the company’s $300 million-plus EBITDA ambition for 2027.
Industry Read-Through
RYAM’s aggressive specialty pricing reset and consolidation-driven market leverage signal a broader inflection in the cellulose and specialty pulp industry, where rationalized capacity and high utilization are shifting bargaining power back to producers. Legacy commodity businesses face structural headwinds from global oversupply and trade friction, while capital-light biomaterials and renewable projects are emerging as the new growth frontier. Investors should watch for similar pricing and portfolio pivots across the sector, as peers seek to monetize core assets and redeploy capital into high-return, sustainable initiatives.